Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492808 | 0.87 | HIF1A (0.46) | SRPK1HIF1AEPAS1MAPKAPK2CA1 | |
| SCHEMBL6491879 | 0.85 | HIF1A (0.46) | HIF1AEPAS1MAPKAPK2SLC2A1CA1 | |
| SCHEMBL6499822 | 0.85 | MAPKAPK2 (0.46) | HIF1AEPAS1MAPKAPK2CA1CA2 | |
| SCHEMBL6498924 | 0.84 | SRPK1 (0.44) | SRPK1HIF1AEPAS1UBE2MDCUN1D1 | |
| SCHEMBL6490805 | 0.84 | HIF1A (0.64) | HIF1AEPAS1 | |
| SCHEMBL6490755 | 0.82 | CA1 (0.51) | HIF1AEPAS1MAPKAPK2SLC2A1CA1 | |
| SCHEMBL6501481 | 0.82 | CA1 (0.52) | HIF1AEPAS1MAPKAPK2CA1CA2 | |
| SCHEMBL6488640 | 0.81 | SRPK1 (0.51) | SRPK1HIF1AEPAS1MAPKAPK2CA1 | |
| SCHEMBL6490778 | 0.81 | MAPKAPK2 (0.46) | HIF1AEPAS1MAPKAPK2SLC2A1CA1 | |
| SCHEMBL6500838 | 0.80 | MAPT (0.56) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SRPK1 3887/4885HIF1A 2476/4885EPAS1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.